Literature DB >> 3516264

Biological therapy of cancer.

K A Foon.   

Abstract

Interferons and monoclonal antibodies are among the most promising biological approaches to cancer treatment which have so far been investigated. Both natural and recombinant interferon-alpha preparations have shown activity in a number of trials in hematologic malignancies, even in previously treated patients; activity in solid tumors, however, has been limited. Unconjugated monoclonal antibodies have been safely administered in several small trials and have had therapeutic value on occasion. In spite of a number of remaining problems and questions, monoclonal antibodies and their conjugates seem likely to find a number of distinct roles in cancer treatment; elimination of micrometastases and purging of bone marrow for grafting may be among these roles.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3516264     DOI: 10.1007/bf01886730

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  53 in total

1.  Virus interference. I. The interferon.

Authors:  A ISAACS; J LINDENMANN
Journal:  Proc R Soc Lond B Biol Sci       Date:  1957-09-12

2.  Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma.

Authors:  T C Merigan; K Sikora; J H Breeden; R Levy; S A Rosenberg
Journal:  N Engl J Med       Date:  1978-12-28       Impact factor: 91.245

3.  Detection of two distinct malignant B cell clones in a single patient using anti-idiotype monoclonal antibodies and immunoglobulin gene rearrangement.

Authors:  S L Giardina; R W Schroff; C S Woodhouse; D W Golde; R K Oldham; M L Cleary; J Sklar; N Pritikin; K A Foon
Journal:  Blood       Date:  1985-11       Impact factor: 22.113

Review 4.  Interferons: biochemical, cell growth inhibitory, and immunological effects.

Authors:  E C Borden; L A Ball
Journal:  Prog Hematol       Date:  1981

5.  Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody.

Authors:  R O Dillman; D L Shawler; J B Dillman; I Royston
Journal:  J Clin Oncol       Date:  1984-08       Impact factor: 44.544

6.  Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon.

Authors:  K A Foon; S A Sherwin; P G Abrams; D L Longo; M F Fer; H C Stevenson; J J Ochs; G C Bottino; C S Schoenberger; J Zeffren
Journal:  N Engl J Med       Date:  1984-11-01       Impact factor: 91.245

7.  Phase II trial of alpha-lymphoblastoid interferon given weekly as treatment of advanced breast cancer.

Authors:  G P Sarna; R A Figlin
Journal:  Cancer Treat Rep       Date:  1985-05

8.  Monoclonal antibodies to myeloid differentiation antigens: in vivo studies of three patients with acute myelogenous leukemia.

Authors:  E D Ball; G M Bernier; G G Cornwell; O R McIntyre; J F O'Donnell; M W Fanger
Journal:  Blood       Date:  1983-12       Impact factor: 22.113

9.  Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial.

Authors:  E C Borden; J F Holland; T L Dao; J U Gutterman; L Wiener; Y C Chang; J Patel
Journal:  Ann Intern Med       Date:  1982-07       Impact factor: 25.391

10.  The generation of monoclonal anti-idiotype antibodies to human B cell-derived leukemias and lymphomas.

Authors:  S L Giardina; R W Schroff; T J Kipps; C S Woodhouse; P G Abrams; H C Rager; A C Morgan; K A Foon
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.